Acerca de Prolong Pharmaceuticals

Acerca de la compañía

Prolong Pharmaceuticals, Inc. develops and markets biopharmaceutical products. Its products include PEG-uricase for the treatment of hyperuricemia; PEG-arginase for the treatment of melanoma and hepatocellular carcinoma; PEG-protein for the treatment of hypovolemic shock; PEG-peptide antibiotic to treat staphylococcus infections; PEG-streptokinase for myocardial infarcts; anti-cancer agents; and Erythropoietin, a biopharmaceutical that provides a solution for anemia. The company also offers custom manufacturing services; and licenses its products to pharmaceutical companies. Prolong Pharmaceuticals, Inc. was founded in 2002 and is based in New Jersey.